Imunon Inc (IMNN): Utang jangka cendhak perusahaan

Imunon, Inc. is developing eco-friendly DNA drug development by minimizing chemical waste. The GURU.Markets service features a line chart of short-term debt load levels, where 0.00 represents the current level of the metric. Financial stability is based on successes in oncology, while operational risks are mitigated by outsourcing plasmid production to certified external partners to eliminate disruptions.

This indicator measures the repayment speed of current credit lines and promissory notes, allowing a risk manager to differentiate planned payments from forced asset liquidation when discounting business value. Analyzing the volume of short-term liabilities is critically important for Imunon, Inc. (IMNN), as the absence of M&A deals leaves the company dependent on future licensing agreements to cover expenses for late-stage clinical trials.